146 related articles for article (PubMed ID: 35937401)
1. Detection of CEA and ProGRP Levels in BALF of Patients with Peripheral Lung Cancer and Their Relationship with CT Signs.
Tian K; Li Z; Qin L
Biomed Res Int; 2022; 2022():4119912. PubMed ID: 35937401
[TBL] [Abstract][Full Text] [Related]
2. Detection of Changes in CEA and ProGRP Levels in BALF of Patients with Peripheral Lung Cancer and the Relationship with CT Signs.
Huang J; Ren K
Contrast Media Mol Imaging; 2023; 2023():1421709. PubMed ID: 36851977
[TBL] [Abstract][Full Text] [Related]
3. [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion].
Liu YQ; Zhang HL; Gao WJ; Lan X; Yuan BJ; Zou JM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan; 26(1):34-8. PubMed ID: 18302890
[TBL] [Abstract][Full Text] [Related]
4. Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer.
Bi H; Yin L; Fang W; Song S; Wu S; Shen J
Lab Med; 2023 Jul; 54(4):372-379. PubMed ID: 36282321
[TBL] [Abstract][Full Text] [Related]
5. [Study on the value of tumor markers ProGRP, CYFRA21-1, NSE and CEA in the differential diagnosis of pleural effusion].
Liu Y; Yu L; Lin J
Zhongguo Fei Ai Za Zhi; 2006 Jun; 9(3):273-6. PubMed ID: 21172161
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic value of serum tumor markers CEA, CYFRA21-1, SCCAg, NSE and ProGRP for lung cancers of different pathological types].
Gao J; Zhang L; Peng K; Sun H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jun; 42(6):886-891. PubMed ID: 35790439
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Value and Clinical Significance of Combined Detection of Serum Markers CYFRA21-1, SCC Ag, NSE, CEA and ProGRP in Non-Small Cell Lung Carcinoma.
Li Q; Sang S
Clin Lab; 2020 Nov; 66(11):. PubMed ID: 33180443
[TBL] [Abstract][Full Text] [Related]
8. [Tumor markers in pleural effusion of patients with lung cancer and patients with tuberculous pleurisy].
Tada A; Kawai H; Matsumoto H; Kimura G; Okada C; Soda R; Takahashi K
Nihon Kokyuki Gakkai Zasshi; 2002 Feb; 40(2):106-12. PubMed ID: 11974864
[TBL] [Abstract][Full Text] [Related]
9. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
10. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
11. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
12. Effects of Bevacizumab Combined with Chemotherapy on CT, CyFRA21-1, and ProGRP and Prognosis of Lung Cancer Patients under Nursing Intervention.
Xi C; Jiang H; Xue Y; Lv Y; Wang C
Comput Math Methods Med; 2022; 2022():9422902. PubMed ID: 35872943
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic value of tumor markers in bronchoalveolar lavage fluid for the peripheral pulmonary carcinoma.
Zhang S; Zhao YF; Zhang MZ; Wu XL
Clin Respir J; 2017 Jul; 11(4):481-488. PubMed ID: 26260621
[TBL] [Abstract][Full Text] [Related]
14. Comparison of serum tumor markers combined with dual-source CT in the diagnosis of lung cancer.
Shan Y; Yin X; Zhao N; Wang J; Yang S
Minerva Med; 2023 Dec; 114(6):795-801. PubMed ID: 33764713
[TBL] [Abstract][Full Text] [Related]
15. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
[TBL] [Abstract][Full Text] [Related]
16. [The value of plasma pro-gastrin-releasing peptide, cytokeratin 19-fragments and carcinoembryonic antigen in patients with lung cancer].
Chen YJ; Jin WD; Yang GY; Zhou YL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct; 25(5):381-3. PubMed ID: 22338231
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
18. Selective application of neuroendocrine markers in the diagnosis and treatment of small cell lung cancer.
Du J; Li Y; Wang L; Zhou Y; Shen Y; Xu F; Chen Y
Clin Chim Acta; 2020 Oct; 509():295-303. PubMed ID: 32592711
[TBL] [Abstract][Full Text] [Related]
19. Exploring the application value of pro-gastrin-releasing peptide in the clinical diagnosis and surgical treatment of medullary thyroid carcinoma.
Miao Q; Lv X; Luo L; Zhang J; Cai B
Cancer Med; 2023 Oct; 12(19):19576-19582. PubMed ID: 37754747
[TBL] [Abstract][Full Text] [Related]
20. [Diagnostic usefulness of selected tumor markers (CA125, CEA, CYFRA 21-1) in bronchoalveolar lavage fluid in patients with non-small cell lung cancer].
Dabrowska M; Grubek-Jaworska H; Domagała-Kulawik J; Bartoszewicz Z; Kondracka A; Krenke R; Nejman P; Chazan R
Pol Arch Med Wewn; 2004 Jun; 111(6):659-65. PubMed ID: 15508787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
